Society Logo
ME/CFS Australia Ltd
Please Click Here To Donate ME/CFS Australia (SA) Inc
 
Facebook
 
ME/CFS AUSTRALIA (SA) INC

Registered Charity 698

Email:
sacfs@sacfs.asn.au

Mailing address:
PO Box 28,
Hindmarsh,
South Australia 5007

Office:
Closed while relocating

Phone:
1300 128 339

Office Hours:
Wednesdays, 10am-3pm

ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.

Disclaimer

ME/CFS Australia (SA) Inc aims to keep members informed of the various research projects, diets, medications, therapies etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
PDF Application Form (PDF, 277KB)
Why become a member?
 

Bioenergy receives warning over medical foods

Monday 15 November 2010

CorvalenNatural Products Insider reports:

Bioenergy Receives Warning Over Medical Foods

Posted in News, Food and Drug Administration (FDA), Government, Product Claims, Ribose

MINNEAPOLIS—FDA issued a warning letter to Bioenergy Inc. regarding the marketing of its Corvalen® products as medical foods, informing the company it does not believe the products meet the statutory definition of a medical food per federal regulations. Instead, the agency considers the Corvalen and Corvalen M® to be misbranded foods and/or new drugs.

With regard to the medical food marketing, the Corvalen products are positioned to address fibromyalgia, chronic fatigue syndrome and cardiovascular disease (CVD). However, FDA stated the statutory definition of a “medical food" per federal regulations to “narrowly constrain the types of products that fit within this category." Specifically, it noted the medical foods must address conditions for which there are distinctive nutritional requirements that cannot be managed by modification of the normal diet.

As the products are currently marketed with therapeutic claims addressing how Corvalen ribose may help address fatigue associated with CVD, chronic fatigue syndrome and fibromyalgia, FDA therefore considers them to be drugs. However, the Corvalen products have not been approved by FDA as new drugs, making them out of regulatory compliance.

The above originally appeared here.

 


Arrow right

More Fibromyalgia News

 


 

blog comments powered by Disqus
Previous Previous Page